Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Labonte, MJ; Wilson, PM; Yang, D; Zhang, W; Ladner, RD; Ning, Y; Gerger, A; Bohanes, PO; Benhaim, L; El-Khoueiry, R; El-Khoueiry, A; Lenz, HJ.
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Ann Oncol. 2012; 23(6):1455-1464 Doi: 10.1093/annonc/mdr445 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Gerger Armin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Background: Lapatinib plus capecitabine emerged as an efficacious therapy in metastatic breast cancer (mBC). We aimed to identify germline single-nucleotide polymorphisms (SNPs) in genes involved in capecitabine catabolism and human epidermal receptor signaling that were associated with clinical outcome to assist in selecting patients likely to benefit from this combination. Patients and methods: DNA was extracted from 240 of 399 patients enrolled in EGF100151 clinical trial (NCT00078572; clinicaltrials.gov) and SNPs were successfully evaluated in 234 patients. The associations between SNPs and clinical outcome were analyzed using Fisher's exact test, Kaplan-Meier curves, log-rank tests, likelihood ratio test within logistic or Cox regression model, as appropriate. Results: There were significant interactions between CCND1 A870G and clinical outcome. Patients carrying the A-allele were more likely to benefit from lapatinib plus capecitabine versus capecitabine when compared with patients harboring G/G (P = 0.022, 0.024 and 0.04, respectively). In patients with the A-allele, the response rate (RR) was significantly higher with lapatinib plus capecitabine (35%) compared with capecitabine (11%; P = 0.001) but not between treatments in patients with G/G (RR = 24% and 32%, respectively; P = 0.85). Time to tumor progression (TTP) was longer in patients with the A-allele treated with lapatinib plus capecitabine compared with capecitabine (median TTP = 7.9 and 3.4 months; P < 0.001), but not in patients with G/G (median TTP = 6.1 and 6.6 months; P = 0.92). Conclusion: Our findings suggest that CCND1A870G may be useful in predicting clinical outcome in HER2-positive mBC patients treated with lapatinib plus capecitabine.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Aged, 80 and over -; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology; Cyclin D1 - genetics; Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives; Disease-Free Survival -; Female -; Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives; Genetic Association Studies -; Humans -; Kaplan-Meier Estimate -; Middle Aged -; Multivariate Analysis -; Neoplasm Metastasis -; Polymorphism, Single Nucleotide -; Proportional Hazards Models -; Quinazolines - administration & dosage; Randomized Controlled Trials as Topic -; Receptor, erbB-2 - metabolism; Treatment Outcome -
Find related publications in this database (Keywords): capecitabine; cyclin D1; lapatinib; metastatic breast cancer; polymorphisms